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Buruli Ulcer
Distribution in
Benin
To the Editor: Mycobacterium
ulcerans disease, commonly called
Buruli ulcer, is an emerging infectious
disease in West Africa (1,2). Several
forms of Buruli ulcer exist; large,
chronic ulcerations or indurated
plaques of the skin are the most fre-
quent manifestations of the disease
(1), and bone is sometimes involved
(3). Little is known about the focal
epidemiology of Buruli ulcer; inci-
dence, prevalence, and other data are
usually reported at the national or dis-
trict level (4). These data convey the
importance of the disease but do not
show the wide variations that occur at
the village level within a given
district. In 2002, we investigated
the disease in an arrondissement
(Gnizounmè) in an area in which
Buruli ulcer is endemic, the commune
of Lalo in Benin. Prevalence rates of
Buruli ulcer varied from 0.58 to 32.62
per 1,000 inhabitants of villages in the
same arrondissement. For Gnizounmè
Arrondissement, the overall preva-
lence was 10.70 per 1,000 inhabitants.
These results confirmed that distribu-
tion of Buruli ulcer must be deter-
mined at geopolitical divisions lower
than district or national levels, as is
frequently assumed to be the case.
An inverse relationship exists
between the prevalence of Buruli
ulcer and distance from the Couffo
River, which drains the arrondisse-
ment of Gnizounmè. A comparison of
the relevant data for Assogbahoué and
Tandji villages shows that the number
of patients per 1,000 inhabitants
increases gradually from 0.58 to
32.62 as the distance from the river
decreases from 10 to 1 km.
Recently, aquatic insects have
been considered potential vectors of
M. ulcerans (5,6). These aquatic
insects can fly many kilometers from
their source (7). This finding may par-
tially explain how patients who live
farther distances from their source of
water become infected, but not as
often as those who live closer. Some
water bugs obtained from water col-
lection points along the Couffo River
in the village of Tandji were found to
be positive for M. ulcerans by using
PCR with specific insertion sequence
2404 as a target (8).
If we consider domestic water
sources in the arrondissement of
Gnizounmè, only Tandji (32.62 Buruli
ulcer patients per 1,000 inhabitants)
used water directly from the Couffo
River. Other villages employed pro-
tected water sources for domestic pur-
poses (boreholes, cisterns, or piped
water from artesian wells). These
results are similar to Barker’s findings
in Uganda, which showed that fami-
lies who used unprotected sources of
water for domestic purposes had high-
er prevalence rates of Buruli ulcer
than those who used boreholes (9).
Consequently, besides the possible
influence of distance from the river on
disease prevalence through potential
vectors, such as insects or other fac-
tors, we hypothesize that the use of
river water for domestic purposes
may also play a role in the elevated
prevalence of the disease in Tandji
village. If this hypothesis is con-
firmed, preventive public health pro-
grams based on strategies that provide
protected water supply systems to vil-
lages must be developed to reduce the
frequency of the disease.
Determining the complex relation-
ship between distance from the
Couffo River and the numbers of
cases and level of protection of water
supply is difficult. Our findings argue
for the need to perform additional epi-
demiologic studies to understand
more completely the key factors that
determine the distribution of the dis-
ease in the entire commune of Lalo. 
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Mycobacterium
tuberculosis Drug
Resistance,
Abkhazia
To the Editor: Drug-resistant
tuberculosis (TB) has been identified
as a major problem in the former
Soviet Union, and was recently sur-
veyed in the Aral Sea regions of
Dashoguz (Turkmenistan) and
Karakalpakstan (Uzbekistan) (1).
However, few data are available for
the Caucasian region and published
reports have focused mainly on pris-
ons (2,3).
We report a drug resistance survey
for first- and second-line anti-TB
drugs conducted in Abkhazia, a
Caucasian region of 8,600 km2 with
approximately 250,000 inhabitants, at
the western end of Georgia on the
Black Sea. The collapse of the Soviet
Union lead to disruption of TB control
activities in all Eastern bloc regions
(4). In Abkhazia, the shortage and
poor quality of drugs, self-medication,
and poor adherence to the therapy
became even more evident during the
war with Georgia in 1993 and the
international embargo that followed. A
TB program based on the World
Health Organization/International
Union against Tuberculosis and Lung
Disease (WHO/IUATLD) recommen-
dations was initiated in Abkhazia with
the support of Médecins Sans
Frontières (MSF) in 1999. In 2000,
monitoring of drug resistance was
started for new cases and previously
treated case-patients. The study was
performed in collaboration with
the Guliripchi TB Hospital, MSF,
and the Istituto Superiore di Sanità
(ISS), a WHO/IUATLD Supranational
Reference Laboratory for anti-TB
drug resistance.
Sputa were collected from all case-
patients attending Gulirip-chi TB
Hospital in Sukhumi, the capital of
Abkhazia, from September 2000 to
April 2004. Patients were either
referred by their practitioners or came
spontaneously because TB was sus-
pected. Diagnosis, treatment, and hos-
pitalization were provided free.
Samples were treated as previously
described (5). Of 489 sputa collected
from individual patients, 447 were
culture positive (246 from new case-
patients and 201 from previously
treated case-patients) and 42 were
culture negative; of these, >90%
showed a negative, doubtful, or 1+
smear result. Susceptibility to first-
line (streptomycin, isoniazid, rifam-
pin, and ethambutol) and second-line
(kana-mycin, ethionamide, capre-
omycin, cycloserine, p-aminosalicylic
acid, and ofloxacin) drugs was deter-
mined by the proportion method on
Middlebrook 7H10 agar. The critical
concentrations used were strepto-
mycin, 2 µg/mL; isoniazid, 0.2
µg/mL; rifampin, 1 µg/mL; ethambu-
tol, 5 µg/mL; kanamycin, 5 µg/mL;
ethionamide, 5 µg/mL; capreomycin,
10  µg/mL;  p-aminosalicylic acid,
2  µg/mL; and ofloxacin, 2 µg/mL
(6–8). Cycloserine was used at a con-
centration of 30 µg/mL (9). If a strain
was resistant to >1 first-line drugs, the
susceptibility to all second-line drugs
was determined.
Data on resistance to the first- and
second-line drugs are given in the
Table. The strains isolated from 35.8%
of the new case-patients and 57.2% of
the previously treated case-patients
were resistant to >1 first-line drugs.
The highest monoresistance was seen
for isoniazid and streptomycin in both
new and previously treated case-
patients while  monoresistance to
rifampin and ethambutol was low
(<1%). Multidrug-resistant (MDR)
strains (i.e., strains resistant to at least
isoniazid and rifampin) were observed
in 4.9% of the new cases and 25.4% of
the previously treated case-patients.
Strains resistant to isoniazid and strep-
tomycin were isolated from 6.9% of
the new cases and 8% of the previous-
ly treated case-patients. Resistance to
second-line drugs was high (15.9% in
new cases and 35.7% in previously
treated case-patients), with the highest
values being observed for kanamycin
(4.5% in new cases and 21.7% in pre-
viously treated case-patients) and
ethionamide (8% in new cases and
16.5% in previously treated case-
patients). Twenty-five percent and
52.9% of the MDR strains isolated
from new and previously treated case-
patients, respectively, showed resist-
ance to >1 second-line drugs. 
Few data have been reported on
drug resistance to first- and second-
line drugs in the former Soviet Union
and in the Caucasian region (1–4).
Overall, in Abkhazia, monoresistance
to isoniazid was higher than in
Karakalpakstan and Dashoguz (1),
while monoresistance to streptomycin
was lower. MDR-TB in new and pre-
viously treated case-patients showed
levels intermediate between these
2 regions. Resistance to kanamycin